{"doc_id": "33378609", "type of study": "Therapy", "title": "", "abstract": "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.\nVaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications.\nThe mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19.\nThis phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States.\nPersons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 \u03bcg) or placebo 28 days apart.\nThe primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2.\nThe trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group).\nMore than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline.\nSymptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001).\nEfficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older.\nSevere Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group.\nModerate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group.\nSerious adverse events were rare, and the incidence was similar in the two groups.\nThe mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease.\nAside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).\nCopyright \u00a9 2020 Massachusetts Medical Society.\n", "Evidence Map": {"Enrollment": [{"term": "high risk for SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 45}, {"term": "complications", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 66}, {"term": "infected", "negation": "negated", "UMLS": {}, "start": 156, "end": 164}, {"term": "SARS-CoV-2", "negation": "negated", "UMLS": {}, "start": 170, "end": 180}, {"term": "SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 161, "end": 181}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mRNA-1273 SARS-CoV-2 Vaccine", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 55, "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}, {"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 21, "end": 28, "has_count": ["2"]}], "has_relation": "N/A"}], "Outcome": [{"term": "Efficacy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 8}, {"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Vaccines are needed to prevent coronavirus disease 2019 ( Covid-19 ) and to protect persons who are at high risk for complications .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 ( SARS-CoV-2 ) , the virus that causes Covid-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This phase 3 randomized , observer-blinded , placebo-controlled trial was conducted at 99 centers across the United States .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 ( 100 \u03bcg ) or placebo 28 days apart .", "Evidence Elements": {"Participant": [{"term": "high risk for SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 45}, {"term": "complications", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 66}], "Intervention": [{"term": "mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 148, "end": 157, "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 172, "end": 179, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2 .", "Evidence Elements": {"Participant": [{"term": "infected", "negation": "negated", "UMLS": {}, "start": 156, "end": 164}, {"term": "SARS-CoV-2", "negation": "negated", "UMLS": {}, "start": 170, "end": 180}], "Intervention": [], "Outcome": [{"term": "Covid-19 illness", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 56}], "Observation": [{"term": "prevention", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 36}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo ( 15,210 participants in each group ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "vaccine", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 104, "has_chemical": [{"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 115, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "More than 96 % of participants received both injections , and 2.2 % had evidence ( serologic , virologic , or both ) of SARS-CoV-2 infection at baseline .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "both injections", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 55, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group ( 56.5 per 1000 person-years ; 95 % confidence interval [ CI ] , 48.7 to 65.3 ) and in 11 participants in the mRNA-1273 group ( 3.3 per 1000 person-years ; 95 % CI , 1.7 to 6.0 ) ; vaccine efficacy was 94.1 % ( 95 % CI , 89.3 to 96.8 % ; P < 0.001 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 77, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, {"term": "mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 194, "end": 203, "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}], "has_relation": "N/A"}], "Outcome": [{"term": "Symptomatic Covid-19 illness", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 28}], "Observation": [{"term": "56.5 per 1000", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 99}, {"term": "3.3 per 1000 person-years", "negation": "affirmed", "UMLS": {}, "start": 212, "end": 237}], "Count": [{"term": "185 participants", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 62}, {"term": "11 participants", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 186}]}, "Evidence Propositions": [{"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "56.5 per 1000", "Outcome": "Symptomatic Covid-19 illness", "Count": ""}, {"Intervention": {"term": "mRNA-1273", "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}], "has_relation": "N/A"}, "Observation": "3.3 per 1000 person-years", "Outcome": "Symptomatic Covid-19 illness", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "", "Count": "185 participants", "Outcome": "Symptomatic Covid-19 illness"}, {"Intervention": {"term": "mRNA-1273", "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}], "has_relation": "N/A"}, "Observation": "", "Count": "11 participants", "Outcome": "Symptomatic Covid-19 illness"}]}, {"Section": "RESULTS", "Text": "Efficacy was similar across key secondary analyses , including assessment 14 days after the first dose , analyses that included participants who had evidence of SARS-CoV-2 infection at baseline , and analyses in participants 65 years of age or older .", "Evidence Elements": {"Participant": [{"term": "SARS-CoV-2 infection", "negation": "affirmed", "UMLS": {}, "start": 161, "end": 181}], "Intervention": [], "Outcome": [{"term": "Efficacy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 8}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Severe Covid-19 occurred in 30 participants , with one fatality ; all 30 were in the placebo group .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Severe Covid-19", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 15}, {"term": "fatality", "negation": "affirmed", "UMLS": {}, "start": 55, "end": 63}], "Observation": [], "Count": [{"term": "30 participants", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 43}, {"term": "one", "negation": "affirmed", "UMLS": {}, "start": 51, "end": 54}, {"term": "all 30 were", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 77}]}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Moderate , transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mRNA-1273", "negation": "affirmed", "UMLS": {}, "start": 86, "end": 95, "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}], "has_relation": "N/A"}], "Outcome": [{"term": "Moderate , transient reactogenicity", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 35}], "Observation": [{"term": "more frequently", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 78}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "mRNA-1273", "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}], "has_relation": "N/A"}], "Observation": "more frequently", "Outcome": "Moderate , transient reactogenicity", "Count": ""}]}, {"Section": "RESULTS", "Text": "Serious adverse events were rare , and the incidence was similar in the two groups .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "two", "negation": "affirmed", "UMLS": {}, "start": 72, "end": 75, "has_relation": "N/A"}], "Outcome": [{"term": "Serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 22}, {"term": "incidence", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 52}], "Observation": [{"term": "rare", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 32}, {"term": "similar", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 64}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "two", "has_relation": "N/A"}], "Observation": "similar", "Outcome": "incidence", "Count": ""}]}, {"Section": "CONCLUSIONS", "Text": "The mRNA-1273 vaccine showed 94.1 % efficacy at preventing Covid-19 illness , including severe disease .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mRNA-1273 vaccine", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 21, "has_chemical": [{"text": "mrna", "maps_to": "C0035696:mrna", "start": 0, "end": 4}, {"text": "vaccine", "maps_to": "C0042210:vaccine", "start": 10, "end": 17, "has_count": ["1273"]}], "has_relation": "N/A"}], "Outcome": [{"term": "efficacy", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 44}, {"term": "Covid-19 illness", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 75}], "Observation": [{"term": "94.1 %", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 35}], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSIONS", "Text": "Aside from transient local and systemic reactions , no safety concerns were identified . ( Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases ; COVE ClinicalTrials.gov number , NCT04470427 . ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "transient local and systemic reactions", "negation": "affirmed", "UMLS": {}, "start": 11, "end": 49}, {"term": "safety concerns", "negation": "negated", "UMLS": {}, "start": 55, "end": 70}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 Massachusetts Medical Society .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}